CL2011001850A1 - Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto. - Google Patents
Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto.Info
- Publication number
- CL2011001850A1 CL2011001850A1 CL2011001850A CL2011001850A CL2011001850A1 CL 2011001850 A1 CL2011001850 A1 CL 2011001850A1 CL 2011001850 A CL2011001850 A CL 2011001850A CL 2011001850 A CL2011001850 A CL 2011001850A CL 2011001850 A1 CL2011001850 A1 CL 2011001850A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- cancers
- treatment
- pharmaceutical composition
- colon cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14888109P | 2009-01-30 | 2009-01-30 | |
US24087309P | 2009-09-09 | 2009-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011001850A1 true CL2011001850A1 (es) | 2012-08-31 |
Family
ID=42077313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011001850A CL2011001850A1 (es) | 2009-01-30 | 2011-07-29 | Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20120004235A1 (es) |
EP (1) | EP2391364A1 (es) |
JP (1) | JP2012516849A (es) |
KR (1) | KR20110122141A (es) |
CN (1) | CN102395368A (es) |
AR (1) | AR075346A1 (es) |
AU (1) | AU2010208042A1 (es) |
BR (1) | BRPI1008155A2 (es) |
CA (1) | CA2749204A1 (es) |
CL (1) | CL2011001850A1 (es) |
CO (1) | CO6410302A2 (es) |
EA (1) | EA201101140A1 (es) |
IL (1) | IL213919A0 (es) |
MX (1) | MX2011008069A (es) |
NZ (1) | NZ593849A (es) |
PE (1) | PE20120112A1 (es) |
SG (1) | SG173454A1 (es) |
TW (1) | TW201038578A (es) |
WO (1) | WO2010088544A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010102219A1 (en) | 2009-03-06 | 2010-09-10 | Rutgers, The State University Of New Jersey | Methylenedioxybenzo [i] phenanthridine derivatives used to treat cancer |
JP2019515025A (ja) | 2016-04-04 | 2019-06-06 | ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー | トポイソメラーゼ毒 |
CN108690034A (zh) * | 2018-01-12 | 2018-10-23 | 兰州大学 | 一种氟化苯并萘啶酮类衍生物、制备方法及用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE640616A (es) | 1962-12-19 | |||
US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
US6140328A (en) | 1997-12-12 | 2000-10-31 | Rutgers, The State University Of New Jersey | Heterocyclic cytotoxic agents |
AU1236401A (en) | 1999-10-29 | 2001-05-14 | Rutgers, The State University Of New Jerey | Heterocyclic cytotoxic agents |
CA2467774C (en) * | 2001-11-14 | 2011-09-20 | Rutgers, The State University | Solubilized topoisomerase poisons |
DE60228484D1 (de) * | 2001-11-14 | 2008-10-02 | Univ Rutgers | Cytotoxische mittel |
US6992089B2 (en) * | 2002-08-09 | 2006-01-31 | Rutgers, The University Of New Jersey | Nitro and amino substituted topoisomerase agents |
US6989387B2 (en) * | 2002-08-09 | 2006-01-24 | Rutgers, The State University Of New Jersey | Nitro and amino substituted topoisomerase agents |
-
2010
- 2010-01-28 TW TW099102428A patent/TW201038578A/zh unknown
- 2010-01-29 AR ARP100100244A patent/AR075346A1/es unknown
- 2010-01-29 US US13/146,555 patent/US20120004235A1/en not_active Abandoned
- 2010-01-29 SG SG2011053949A patent/SG173454A1/en unknown
- 2010-01-29 PE PE2011001416A patent/PE20120112A1/es not_active Application Discontinuation
- 2010-01-29 CA CA2749204A patent/CA2749204A1/en not_active Abandoned
- 2010-01-29 CN CN2010800068220A patent/CN102395368A/zh active Pending
- 2010-01-29 KR KR1020117020024A patent/KR20110122141A/ko not_active Application Discontinuation
- 2010-01-29 MX MX2011008069A patent/MX2011008069A/es not_active Application Discontinuation
- 2010-01-29 EA EA201101140A patent/EA201101140A1/ru unknown
- 2010-01-29 AU AU2010208042A patent/AU2010208042A1/en not_active Abandoned
- 2010-01-29 JP JP2011548351A patent/JP2012516849A/ja active Pending
- 2010-01-29 EP EP10703578A patent/EP2391364A1/en not_active Withdrawn
- 2010-01-29 NZ NZ593849A patent/NZ593849A/en not_active IP Right Cessation
- 2010-01-29 BR BRPI1008155A patent/BRPI1008155A2/pt not_active IP Right Cessation
- 2010-01-29 WO PCT/US2010/022625 patent/WO2010088544A1/en active Application Filing
-
2011
- 2011-07-04 IL IL213919A patent/IL213919A0/en unknown
- 2011-07-29 CL CL2011001850A patent/CL2011001850A1/es unknown
- 2011-07-29 CO CO11095925A patent/CO6410302A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA201101140A1 (ru) | 2012-03-30 |
SG173454A1 (en) | 2011-09-29 |
MX2011008069A (es) | 2011-09-06 |
WO2010088544A1 (en) | 2010-08-05 |
WO2010088544A8 (en) | 2011-07-28 |
PE20120112A1 (es) | 2012-02-27 |
CO6410302A2 (es) | 2012-03-30 |
CN102395368A (zh) | 2012-03-28 |
CA2749204A1 (en) | 2010-08-05 |
NZ593849A (en) | 2014-02-28 |
BRPI1008155A2 (pt) | 2016-03-08 |
EP2391364A1 (en) | 2011-12-07 |
IL213919A0 (en) | 2011-07-31 |
AR075346A1 (es) | 2011-03-23 |
US20120004235A1 (en) | 2012-01-05 |
JP2012516849A (ja) | 2012-07-26 |
AU2010208042A1 (en) | 2011-07-21 |
KR20110122141A (ko) | 2011-11-09 |
TW201038578A (en) | 2010-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
CL2016001733A1 (es) | Compuestos intermediarios para la preparación de compuestos derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer div. sol. 3415-12. | |
CL2008001047A1 (es) | Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata. | |
CL2012001627A1 (es) | Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer. | |
ECSP11011390A (es) | Compuestos espiro-amidas sustituidas | |
PH12015500263A1 (en) | New bicyclic derivatives | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
CL2007002994A1 (es) | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
CL2012000324A1 (es) | Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
PA8740901A1 (es) | Compuestos organicos | |
CL2015002591A1 (es) | Entidades químicas. | |
EP2550266A4 (en) | HETEROCYCLIC COMPOUNDS FOR KINASE INHIBITION | |
CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
CR20110467A (es) | Derivados de benzofuranilo como inhibidores de la glucoquinasa | |
CO6480975A2 (es) | Mimetico de smac | |
CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
CL2010000320A1 (es) | Un compuesto 8-(1,3-dihidro-isoindol-2-ilmetil)-2,9-dihidro-1,2,7,9-tetraaza-fenalen-3-ona, como inhibidor de parp; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
CL2008001213A1 (es) | Uso de compuestos derivados de piridin-4-il-benceno-1,4-diamino sustituidos por alquindol para preparar un medicamento para el tratamiento de un trastorno proliferativo tal como el cancer. | |
EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
AR067769A1 (es) | Derivado de ditiazol para el tratamiento del cancer | |
BR112012023836A2 (pt) | composto tricíclicos e inibidores de pbk contendo os mesmos | |
CL2008002767A1 (es) | Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva. | |
CO6341625A2 (es) | Derivados de indol como agentes anticáncer |